Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Dreamy Small-Cap Stocks
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Hedge Your Portfolio with the Equity Bear ETF
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 6.67% |
| STEIN MART I | SMRT | 5.38% |
| ALLIANCE FIB | AFOP | 5.21% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Forest Labs ( FRX - Analyst Report ) and Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, recently signed a collaboration agreement. The companies will work on the development of novel mPGES-1 inhibitors for the treatment of chronic inflammatory conditions, including pain.
Potential candidates have already been identified by Glenmark. Glenmark is conducting pre-clinical studies with these candidates prior to the initiation of human studies.
Glenmark will receive an upfront payment of $6 million from Forest Labs. Moreover, Forest Labs will pay $3 million to fund the next phase of work. Additional payments will be made by Forest Labs in fiscal 2014 to support the development program. Once phase I development is completed, Forest Labs has an exclusive option to acquire licensing rights to the program.
With this deal, Glenmark is gaining a strong commercialization partner like Forest Labs. Meanwhile, the deal is in line with Forest Labs’ efforts to expand its pipeline. Forest Labs is facing tough times with Lexapro losing patent protection. Over the past few years, Forest Labs has been very active in signing in-licensing and partnership deals with the intention of expanding its pipeline. The company has licensing agreements with several companies like Almirall SA, AstraZeneca ( AZN - Analyst Report ) , and Ironwood Pharma ( IRWD - Snapshot Report ) among others.
We currently have a Neutral recommendation on Forest Labs, which carries a Zacks #3 Rank (Hold). Following the release of second quarter results, Forest Labs once again cut its outlook for fiscal 2013. More than Lexapro’s genericization, the cut in Namenda’s guidance is disappointing as Namenda is currently the main contributor to the company’s top line. Moreover, the performance of new products especially Teflaro, has been below expectations. We note that Namenda will face generic competition in early 2015 putting another $1+ billion at risk.
Both Ironwood Pharma and AstraZeneca are Zacks #2 Rank (Buy) stocks.
Read the full reports :
Snapshot Report on IRWD
Analyst Report on FRX
Analyst Report on AZN